Hypoparathyroidism Market to Reach USD 2.06 Billion by 2034

Pune, India - December 2025 - The global Hypoparathyroidism Market, valued at USD 1.21 billion in 2024, is projected to reach USD 2.06 billion by 2034, growing at a 5.5% CAGR (2025-2034), according to Exactitude Consultancy. Increasing incidence of post-thyroidectomy hypoparathyroidism, improved diagnosis of chronic hypocalcemia, and expanding use of recombinant parathyroid hormone (PTH) therapies are key market growth drivers.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71995

Market Summary
The Hypoparathyroidism Market is expanding rapidly as awareness grows around this rare endocrine disorder characterized by insufficient parathyroid hormone (PTH) production, leading to chronic hypocalcemia, neuromuscular dysfunction, seizures, kidney complications, and decreased quality of life. The majority of cases arise post-thyroid or parathyroid surgery, making it a significant iatrogenic condition.

Diagnosis is improving with greater adoption of serum calcium monitoring, PTH assays, vitamin D metabolite assessment, kidney imaging, and endocrinology referral pathways. Standard treatment using oral calcium and active vitamin D remains widely used, but limitations in long-term efficacy and renal burden are prompting growing demand for PTH replacement therapies such as rhPTH (1-84) and next-generation analogs under development.

North America leads due to high surgical volumes and availability of PTH therapies, while Asia-Pacific is the fastest-growing region due to expanding endocrine care and rising thyroid surgery rates.

Key Takeaways
• 2024 Market Size: USD 1.21 Billion
• 2034 Forecast: USD 2.06 Billion
• CAGR: 5.5% (2025-2034)
• Post-surgical hypoparathyroidism remains the largest patient segment
• Growing adoption of PTH replacement therapy improving long-term outcomes
• Asia-Pacific expected to witness rapid expansion due to improved endocrine care

Market Drivers
• Rising incidence of thyroid cancer & thyroidectomy procedures
• Growing clinical focus on chronic hypocalcemia management
• Advancements in recombinant PTH and long-acting hormone analogs
• Better diagnostic access in emerging healthcare markets
• Increased awareness among primary care & endocrine specialists

Segmentation Snapshot
By Treatment Type
• Calcium Supplements
• Active Vitamin D (Calcitriol, Alfacalcidol)
• Recombinant PTH (rhPTH 1-84)
• Emerging Long-Acting PTH Analogues
• Adjunctive Therapies

By Disease Type
• Post-Surgical Hypoparathyroidism (Largest Segment)
• Autoimmune
• Genetic / Congenital
• Idiopathic

By Diagnosis Method
• Serum Calcium Testing
• PTH Assays
• Vitamin D Level Testing
• Renal Ultrasound
• Neuro-muscular Symptom Evaluation

By End User
• Hospitals
• Endocrinology Clinics
• Specialty Treatment Centers
• Diagnostic Laboratories
• Research Institutes

By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71995/hypoparathyroidism-market

Recent Developments
• Increased clinical use of recombinant PTH for chronic hypoparathyroidism.
• Trials underway for long-acting PTH formulations with improved safety profiles.
• Enhanced patient monitoring using digital calcium-level tracking tools.
• Rising thyroid surgery rates driving larger patient pool identification.

Expert Quote - Irfan Tamboli, Business Development Executive
"Hypoparathyroidism is gaining long-overdue clinical attention, especially with next-generation PTH therapies reshaping long-term management and improving quality of life for patients worldwide."

Conclusion
The Hypoparathyroidism Market will grow steadily through 2034 as technological advances enhance diagnostic accuracy, surgical volumes increase, and hormone replacement therapies evolve. Companies focusing on PTH analog development, digital monitoring platforms, and endocrine specialty care innovations will lead the next phase of market growth.

This report is also available in the following languages : Japanese (副甲状腺機能低下症市場), Korean (부갑상선기능저하증 시장), Chinese (甲状旁腺功能减退症市场), French (Marché de l'hypoparathyroïdie), German (Markt für Hypoparathyreoidismus), and Italian (Mercato dell'ipoparatiroidismo), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71995

Related Reports

Severe Hypoglycemia Market
https://exactitudeconsultancy.com/reports/72047/severe-hypoglycemia-market

X-linked Hypophosphatemia Market
https://exactitudeconsultancy.com/reports/72653/x-linked-hypophosphatemia-market

Hypoactive Sexual Disorder Market
https://exactitudeconsultancy.com/reports/72678/hypoactive-sexual-disorder-market

Needles Market
https://exactitudeconsultancy.com/reports/73447/needles-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.